In this segment from Tuesday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck (NYSE:MRK), and why its pipeline is one investors should be excited about today.
Amazingly, Merck looks as though it will be the first to market with its PD1 immuno-oncology drug 3475, beating the seeming favorite Bristol-Myers Squibb's (NYSE:BMY)nivolumab. David tells investors why he's excited about this coming megablockbuster and its potential for off-label use, as well as which key trials for the drug investors will want to watch for this year.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
David Williamson owns shares of Merck. Michael Douglass and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.